Literature DB >> 1682160

Amylin injection causes elevated plasma lactate and glucose in the rat.

A A Young1, M W Wang, G J Cooper.   

Abstract

Intravenous injections of 25.5 nmol rat amylin into fasted anesthetized rats caused a rapid increase in plasma lactate followed by an increase in plasma glucose; there was a transient fall in blood pressure. Subcutaneous injection of 25.5 nmol amylin also caused increases in lactate and glucose but did not change blood pressure. Similar responses were observed during somatostatin infusion and in the absence of changes in catecholamines. These results fit with a scheme in which amylin elicits muscle glycogenolysis, release of lactate, and increased hepatic gluconeogenesis due to increased supply of substrate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682160     DOI: 10.1016/0014-5793(91)81113-m

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  5 in total

1.  Circadian anorectic effects of peripherally administered amylin in rats.

Authors:  T A Lutz; E Del Prete; M M Szabady; E Scharrer
Journal:  Z Ernahrungswiss       Date:  1995-09

Review 2.  Amylin, amyloid and age-related disease.

Authors:  G J Cooper; C A Tse
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

3.  Plasma amylin and insulin concentrations in normoglycemic and hyperglycemic cats.

Authors:  T A Lutz; J S Rand
Journal:  Can Vet J       Date:  1996-01       Impact factor: 1.008

4.  NF-κB-dependent airway inflammation triggers systemic insulin resistance.

Authors:  Travis J Cyphert; Robert T Morris; Lawrence M House; Tammy M Barnes; Yolanda F Otero; Whitney J Barham; Raphael P Hunt; Rinat Zaynagetdinov; Fiona E Yull; Timothy S Blackwell; Owen P McGuinness
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-09-16       Impact factor: 3.619

Review 5.  Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases.

Authors:  Nina Sonne; Morten A Karsdal; Kim Henriksen
Journal:  Mol Metab       Date:  2020-11-07       Impact factor: 7.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.